No, vulvoscopy is not required to confirm lichen sclerosus
Lichen sclerosus is a clinical diagnosis that does not require vulvoscopy or any specialized imaging technique for confirmation. The diagnosis is made based on the characteristic clinical appearance of the lesions 1.
When Clinical Diagnosis Alone is Sufficient
The British Association of Dermatologists guidelines explicitly state that "LS is a clinical diagnosis and a confirmatory biopsy is not always necessary when the typical clinical features are present" 1. This is particularly true in:
- Children - where clinical features are usually straightforward
- Men - where typical presentations are diagnostic
- Any patient with classic findings: porcelain-white papules and plaques, areas of ecchymosis, follicular dells, and characteristic distribution patterns
When to Consider Biopsy (Not Vulvoscopy)
A tissue biopsy—not vulvoscopy—should be considered in specific clinical scenarios 1:
- Suspicion of malignancy: persistent hyperkeratosis, erosion, erythema, or new warty/papular lesions
- Atypical features or diagnostic uncertainty
- Young adult women of reproductive age: since LS is less common in this population, biopsy should be considered before starting treatment 1
- Treatment failure: disease that fails to respond to adequate therapy
- Pigmented areas: to exclude melanocytic proliferation
- Extragenital disease: when features mimic morphoea
The Role of Vulvoscopy
Vulvoscopy is not mentioned in the authoritative British Association of Dermatologists 2018 guidelines as a diagnostic tool for lichen sclerosus 1. The guidelines focus on clinical examination and selective use of biopsy for histological confirmation when needed.
Practical Diagnostic Approach
Start treatment based on clinical diagnosis when typical features are present:
- Porcelain-white plaques
- Ecchymosis
- Characteristic anogenital distribution
- Associated symptoms (pruritus, dyspareunia)
Reserve biopsy for the specific scenarios listed above, taking the sample from the most active sclerotic area with good clinicopathological correlation 1.
Critical Pitfall to Avoid
Do not delay treatment waiting for specialized imaging or unnecessary confirmatory testing when classic clinical features are present. Early treatment with ultra-high-potency topical corticosteroids can prevent scarring and reduce the 3-5% malignancy risk 1, 2. The emphasis should be on prompt clinical recognition and initiation of appropriate therapy rather than pursuing unnecessary diagnostic procedures.